10 Updates

Why Did One Of The World's Largest Generic Drug Makers Exit China?

Feb 3 2014, 6:36pm CST | by

The week of JP Morgan’s January 2014 healthcare conference in San Francisco, Actavis, one of the world’s largest generic pharmaceutical companies, made a splash by emphasizing its emerging market...

Filed under: news

 
 
 

24 weeks ago

Why Did One Of The World's Largest Generic Drug Makers Exit China?

Feb 3 2014, 6:36pm CST | by

The week of JP Morgan’s January 2014 healthcare conference in San Francisco, Actavis, one of the world’s largest generic pharmaceutical companies, made a splash by emphasizing its emerging market strategy, just not the way most investors anticipated.  Where most pharmaceutical companies have elevated the market opportunity in China as key to their revenue growth and profitability, Actavis made clear it views the risks in China as well beyond the potential benefits.  In a much quoted interview at the JP Morgan event, Actavis’ CEO Paul Bisaro stated “If we’re going to allocate capital, we’re going to do so where we can get the most amount of return for the least amount of risk.  And China is just too risky.”

What exactly is Actavis walking away from, and why?  In terms of market size, estimates are that by 2015, China’s generic market will be close to $82 billion .  Actavis is hardly a marginal player in the global generic space and at face value should be one of the companies well positioned to take advantage of China’s growing appetite for generic drugs.  The company is certainly not a passive bystander in shaping markets.  Under Bisaro’s leadership, Actavis has been one of the key players pushing M&A deals in an effort to consolidate the generic drug marketplace.  For a company like Actavis to back away from China publicly, a decision they began to make good on late in January when they sold their stake in a subsidiary in Foshan, China, something more is at work.

The question is what, and whether Actavis’ decision sheds any light on either China or the global generic drug market.  It is essential to distinguish between these two ideas.  Actavis’ decision may be best understood as a statement about China’s diminishing hospitality towards foreign businesses in general, and pharmaceutical companies specifically .  Or, Actavis as a business, with its unique footprint in China within the generic market, might not have been in a position to grow its Chinese market share profitably.

Because of this summer’s events surrounding GSK’s China operations , and allegations of improprieties in both its Chinese sales and clinical trial arms, global pharmaceutical and medical device companies are on-guard over new corruption crackdowns that seem to disproportionately emphasize the wrongdoings of foreign companies.  As Tracy Staton with FiercePharma quite eloquently captured it with respect to the GSK anti-corruption charges from this past summer, “while stamping out corruption was the stated intent, drug prices are the subtext. It’s a sort of price squeeze by prosecution.”  Industry watchers have been somewhat placated over the Chinese government’s recent pursuit of bribery charges against China’s largest pharmaceutical distributor Sinopharm, a domestic company.  To see a domestic company get caught up in China’s pursuit of more transparent pricing – if that is in fact what motivates the government – is encouraging to those fearful of discrimination against foreign companies.

The broader questions that Actavis’ CEO pointed towards as a rationale for the company’s exit from China are not wrong.  Surveys conducted by various American and European business groups in China all point towards worrying trends which suggest China is becoming fundamentally less hospitable to foreigners than in years past.  Favoritism towards domestic companies by government purchasing is nothing unique to China, unless you consider that China’s 144,500 State Owned Enterprises (SOE) represent 35% of the country’s industrial revenue (a percentage many economists believe greatly under-represents the economic impact of SOEs).    Add to the SOE’s position the role of the Chinese government as purchaser of great amounts of pharmaceuticals and medical devices, and you can see what the comments of Actavis’ CEO ring true to many.

In addition, the unique pressures facing businesses selling into China’s healthcare economy make the trade between market size and profit more acute and uncertain than ever.  No one doubts that demographics and disease data point towards incredible demand for healthcare goods and services in China.  What is being questioned is whether foreign companies can profitably capture the opportunity.  One of GSK’s first responses to the events of this summer was to dramatically cut prices , a move that left many wondering less about the company’s guilt and more about what was really motivating the Chinese authorities.  Companies like GSK and Actavis now understand more clearly than they did twelve months ago that healthcare in China is an increasingly political matter, that their biggest customer – the government – is also responsible for the broken funding mechanism that has made access and affordability for healthcare in China one of the most basic and pervasive broken promises the government in Beijing is singularly responsible for.

These issues are solvable.  China’s reimbursement mechanism between the Ministry of Finance and Ministry of Health, as well as hospitals and patients, can be fixed.  The basic government-provided healthcare insurance can become more sophisticated relative to what it pays for.  New drugs can be added to China’s national formulary (known as the Essential Drug List, or EDL).  And, as many overseas drug makers hope, the purchasing power and brand attachment for China’s growing middle class can ensure that, where possible, consumers choose western medicines even if these come at a higher cost.  This has always been the potential, even if the turbulence in the market over the last year has caused some to lose faith that China would develop into a viable market.

If these positive steps were to take place, then would we think differently about Actavis’ decision today?  Or, to be even more direct, are we allowing the events of the past 12 months to obscure more basic business strategy issues at play with Actavis’ specifically?  By the time the Actavis’ announcement went out in mid-January 2014, the company had around 200 employees in China, generating less than $7 in profit .  This is an extremely un-impressive performance for the world’s second largest generic drug manufacturer in what is quickly becoming the world’s largest generic market.  Actavis’ growth mode globally has been heavy on M&A activity, becoming one of the key actors consolidating the generic market.  Is Actavis leaving China now because the reasons the company goes into any market, emerging or otherwise, are not yet a factor in China?  Or, even more cynically, is Actavis’ exit evidence of a corporate strategy that emphasized M&A activity at the cost of a coherent strategy for China, the market most players believe will be the most important market for global generic manufacturers in the coming decades?

The company is widely viewed as one of the leading candidates to acquire Pfizer’s “value products business” – a euphemism for Pfizer’s prized branded generic business.  With opportunities like this to further consolidate the global generic market, is Actavis better served to focus on opportunities outside of China?  The unique pressures of the generic business in China make this question even more important to answer.  Price pressures on generics are going to further intensify.  The government is going to maintain an unrelenting and uncompromising focus on the part of its healthcare system where it believes cost controls are easiest to find, and generic pharmaceuticals top the list.  The Chinese government’s ongoing efforts to incentivize a domestic life science industry are going to further skew the commercial opportunities in the generic market initially, and the patent-protected products tomorrow, as technology transfer expectations between foreign companies and domestic Chinese actors accelerates.

In other sectors of the Chinese economy, when companies have encountered similar frustrations, CEOs have shrugged their shoulders and essentially said, “we don’t really have a choice – we have to be in China.”  Actavis clearly does not believe this, which is either a great tribute to their vision, or a decision that took advantage of a unique moment in time when the company could exit the Chinese market when Actavis’ overall China strategy would not be questioned.  If the Chinese government is successful disrupting the generic market both domestically and internationally, will Actavis sooner or later have to deal with the market forces that today led them to exit China?  If so, Actavis will need to use the next decade to shape global pharma IP standards and the market itself in ways that prevent the Chinese government’s actions from distorting not only its domestic market, but those Actavis is reliant on today.

Source: Forbes Business

 
Update
10

6 weeks ago

RM47mil KWSG contributions still unclaimed

Jun 9 2014 7:54am CDT | Source: Business Times Malaysia

Cambodia's Famous Battambang Circus
KUALA LUMPUR: About RM47 million of contributions in the Teachers Provident Fund (KWSG) still remain unclaimed, the Dewan Rakyat ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
9

6 weeks ago

Gold shop lost almost RM1mil

Jun 9 2014 3:50am CDT | Source: Business Times Malaysia

Collingwood Magpies Training Session
KANGAR: A gold shop owner lost almost RM1 million after after the safe on in his shop was broken into by robbers. ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
8

6 weeks ago

Motion to debate MAS losses in Dewan Rakyat rejected

Jun 9 2014 3:39am CDT | Source: Business Times Malaysia

Federal Aviation Administration Bans All US Flights To Israel
KUALA LUMPUR: AN emergency motion to debate the losses incurred by Malaysia Airlines last year, amounting to RM1.2 billion was rejected by the Dewan Raky ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
7

6 weeks ago

MH370 Tragedy: Hisham: RM27.6 mil spent on 1st phase of SAR

Jun 9 2014 2:11am CDT | Source: Business Times Malaysia

KUALA LUMPUR: Malaysia spent some RM27.6 million in its first phase of the search operations for missing Malaysia Airline flight MH370, said Acting Transport Mi ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
6

6 weeks ago

9.1m litres of diesel seized in a month

Jun 8 2014 1:11am CDT | Source: Business Times Malaysia

INDIA-CHINA-DIPLOMACY-TRADE
PUTRAJAYA: The Domestic Trade, Cooperatives, and Consumerism ministry has seized some 9.1 million litres of diesel and property worth RM58 million since mounting ‘Operasi Diesel Selatan’ in the southern st ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
5

6 weeks ago

Girl, 9, awarded RM2.78m compensation for medical negligence

Jun 6 2014 4:56am CDT | Source: Business Times Malaysia

Government Weekly Cabinet Meeting
KUALA LUMPUR: A nine-year-old girl who suffered brain damage during her birth at a government hospital was awarded over RM2.78 million ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
4

6 weeks ago

Malaysia's total trade in April up 12pc

Jun 5 2014 11:52pm CDT | Source: Business Times Malaysia

KUALA LUMPUR: Malaysia's total trade in April 2014 rose by 12 per cent from a year ago to RM123.86 billion due to growing trading activities, International Trade and Industry Minister Datuk Seri Mus ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
3

6 weeks ago

Works Ministry to spend RM20m for upgrading works at 50 accident black spots

Jun 4 2014 11:35pm CDT | Source: Business Times Malaysia

Iskandar Johor Open - Previews
JOHOR BARU: The Works Ministry will implement upgrading works at 50 accident prone locations in the country that have been identified this year involving an allocation of RM20 mill ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
2

6 weeks ago

Najib launches loan scheme for Ramadan traders

Jun 4 2014 10:24pm CDT | Source: Business Times Malaysia

EurAsia Cup presented by DRB-HICOM - Day One
PUTRAJAYA: Prime Minister Datuk Seri Najib Razak today launches RM45 million Ramadan Bazaar Sch ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 
Update
1

7 weeks ago

Residents bring up objection against Kidex to Suhakam

Jun 4 2014 4:49am CDT | Source: Business Times Malaysia

PETALING JAYA: A group of 20 Petaling Jaya residents held a meeting with the Human Rights Commission of Malaysia (Suhakam) over their objection against the proposed RM2.2 billion ...
Source: Business Times Malaysia   Full article at: Business Times Malaysia
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

OPEC daily basket price closes higher
Vienna, July 23 (IANS/WAM) The basket of 12 crude oils of the Organization of Petroleum Exporting Countries (OPEC) stood at $105.74 a barrel Tuesday, against $105.07 Monday, according to the OPEC Secretariat.
 
 
How to make your kids eat veggies
New York, July 23 (IANS) Do you find it hard to make your kids eat vegetables? Then do not tell them vegetables are good for them as children are less likely to eat healthy foods when they hear about their benefits, says a study.
 
 
Impulsive behaviour linked to brain connectivity
London, July 23 (IANS) In what could help better understand behavioural problems and social adaptation difficulties in children, researchers have found that patterns of brain connectivity are linked with impulsive behaviour.
 
 
Vitamin D deficiency increases schizophrenia risk
London, July 23 (IANS) Individuals with Vitamin D deficiency are twice as likely to be diagnosed with schizophrenia as compared to those who have sufficient levels of the vitamin, says a study.
 
 
 

Latest from the Network

OPEC daily basket price closes higher
Vienna, July 23 (IANS/WAM) The basket of 12 crude oils of the Organization of Petroleum Exporting Countries (OPEC) stood at $105.74 a barrel Tuesday, against $105.07 Monday, according to the OPEC Secretariat. The new...
Read more on Business Balla
 
Tourists evacuated as typhoon Matmo approaches
Beijing, July 23 (IANS) A total of 1,477 tourists on an island in east China's Zhejiang province were evacuated as typhoon Matmo approached, officials said Wednesday. The tourists on Nanji Island boarded 14 additional...
Read more on Politics Balla
 
Katie Price regrets love tattoos
Los Angeles, July 23 (IANS) Former model Katie Price has revealed that she regrets having the names of her ex-lovers tattooed on her body. The 36-year-old is haunted by the tattoos that she got while she was married...
Read more on Celebrity Balla
 
How to make your kids eat veggies
New York, July 23 (IANS) Do you find it hard to make your kids eat vegetables? Then do not tell them vegetables are good for them as children are less likely to eat healthy foods when they hear about their benefits,...
Read more on Apple Balla
 
Impulsive behaviour linked to brain connectivity
London, July 23 (IANS) In what could help better understand behavioural problems and social adaptation difficulties in children, researchers have found that patterns of brain connectivity are linked with impulsive...
Read more on Apple Balla
 
Austrian cyclist starts 'coast-to-coast' one-man race in Russia
Vladivostok (Russia), July 23 (IANS) Austrian extreme cyclist Wolfgang Fasching started one-man race Wednesday from Vladivostok via Moscow to St. Petersburg in an attempt to cover 10,000 kilometres in 24 days. The...
Read more on Sport Balla
 
Vitamin D deficiency increases schizophrenia risk
London, July 23 (IANS) Individuals with Vitamin D deficiency are twice as likely to be diagnosed with schizophrenia as compared to those who have sufficient levels of the vitamin, says a study. The skin naturally...
Read more on Apple Balla
 
Age increases belief in love at first sight
London, July 23 (IANS) Love at first sight is not the sole property of the young. As you age, you are more likely to believe in love at first sight, an interesting study reveals. Those who are middle-aged are 46...
Read more on Apple Balla
 
Richard Gere romancing brunette
Richard Gere has sparked speculation he has a new girlfriend. The 'Pretty Woman' actor had been romancing 'Top Chef' host Padma Lakshmi for the last few months, but he was seen holding hands with a brunette who was ''...
Read more on Celebrity Balla